Evidence map›Paper›PMID 40999189›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

The association of oxaliplatin-induced peripheral neuropathy and falls with intercycle delays and early discontinuation of chemotherapy in older colorectal cancer patients.

Robert B Hines, Xiang Zhu, Christopher Schoborg, Stephanie Sutton, Eunkyung Lee, Shunpu Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Incidence and associated factors of falls in patients with chemotherapy-induced peripheral neuropathy: a scoping review and evidence mapping.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert B HinesDepartment of Population Health Sciences, University of Central Florida, College of Medicine, 6900 Lake Nona Blvd, Orlando, FL, 32827, USA. robert.hines@ucf.edu.ORCID http://orcid.org/0000-0001-7139-3102
Xiang ZhuCollege of Medicine, University of Central Florida, Orlando, FL, USA.
Christopher SchoborgFlorida State University, Tallahassee, FL, USA.
Stephanie SuttonCollege of Medicine, University of Central Florida, Orlando, FL, USA.
Eunkyung LeeCollege of Health Professions and Sciences, University of Central Florida, Orlando, FL, USA.
Shunpu ZhangCollege of Sciences, University of Central Florida, Orlando, FL, USA.

Funding

Prevention and Treatment of Oxaliplatin-Induced Peripheral NeuropathyR03CA241788 · NCI · UNIVERSITY OF CENTRAL FLORIDA · PI HINES, ROBERT BROOKS · 2020 to 2020
$149k
NCI NIH HHS 1 R03 CA241788-01A1NCI NIH HHS R03 CA241788
6 · The paper itself

Abstract

purposeOxaliplatin chemotherapy improves survival in patients with colorectal cancer, but a common dose-limiting toxicity is oxaliplatin-induced peripheral neuropathy (OIPN). The purpose of this study was to assess the association between OIPN and falls with intercycle delays and early discontinuation of oxaliplatin chemotherapy.

methodsColorectal cancer patients in this study were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims data (SEER-Medicare). All patients were ≥ 66 years of age at diagnosis. OIPN and falls were considered time-dependent exposures and were identified by diagnosis codes. Intercycle chemotherapy delay was defined as receipt of chemotherapy ≥ 7 days after the planned chemotherapy date. Early discontinuation was determined according to the chemotherapeutic regimen (infusional 5-FU < 6 cycles, oral capecitabine < 4 cycles). Poisson regression with generalized estimating equations and 95% confidence intervals was used to obtain adjusted incidence rate ratios (IrR) and rate differences (IrD) for intercycle delays and risk ratios (RR) and risk differences (RD) for early discontinuation.

resultsA total of 3802 patients were available for analysis. Intercycle oxaliplatin delay occurred in 57.7% of subjects (n = 2194). OIPN (IrR = 1.87: 95% CI, 1.67-2.10; IrD = 2.09 delays/81 person-days: 95% CI, 1.48-2.69) and falls (IrR = 2.62: 95% CI, 2.06-3.34; IrD = 3.30 delays/81 person-days: 95% CI, 1.96-4.64) were associated with increased rates of delay. Early discontinuation of chemotherapy occurred in 22.1% of patients (n = 841). OIPN (RR = 2.51: 95% CI, 1.78-3.55; RD = 7.2%; 95% CI, 3.0-11.4%) and falls (RR = 2.19; 95% CI, 1.24-3.85) were also associated with increased risks of early discontinuation.

conclusionPatients who experience intercycle delays and early discontinuation of scheduled chemotherapy treatment may experience poorer cancer-related outcomes. Therapeutics to prevent and treat OIPN and fall prevention strategies are needed to decrease the likelihood of chemotherapy treatment disruptions in older colorectal cancer patients.

Indexed as

Accidental FallsAntineoplastic AgentsColorectal NeoplasmsOrganoplatinum CompoundsPeripheral Nervous System DiseasesAgedAged, 80 and overCapecitabineFemaleHumansIncidenceMaleMedicareOxaliplatinSEER ProgramTime FactorsAntineoplastic AgentsCapecitabineOrganoplatinum CompoundsOxaliplatin5-FluorouracilChemotherapy-induced peripheral neuropathyColorectal cancerFallsOxaliplatinOxaliplatin-induced peripheral neuropathyTreatment disruption

Identifiers

PMID40999189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.